Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on bleeding events and net clinical benefit
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
NCT00120406
Percutaneous Coronary Intervention (PCI) With Drug-Eluting Stents (DES) Versus Coronary Artery Bypass Graft (CABG) for Patients With Significant Left Main Stenosis
NCT00176397
Zilver PTX Drug-Eluting Peripheral Stent Study
NCT01348425
Zilver® PTX™ Global Registry
NCT01094678
Iliac, Common and External (ICE) Artery Stent Trial
NCT01305174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the IDEAL-PCI Extended Registry an additional deescalation arm with reduction of the standard dual antiplatelet therapy (DAPT) dosis in case of low platelet reactivity to P2Y12 Inhibition or Aspirin with or without bleeding is implemented.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bleeding prevention group
Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
DAPT reduction
Reduction of standard dose DAPT due to low platelet reactivity
DAPT on-target
Standard DAPT within the therapeutic window of platelet reactivity
Ischemia prevention group
Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
DAPT on-target
Standard DAPT within the therapeutic window of platelet reactivity
DAPT intensification
Intensification of standard dose DAPT due to high platelet reactivity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DAPT reduction
Reduction of standard dose DAPT due to low platelet reactivity
DAPT on-target
Standard DAPT within the therapeutic window of platelet reactivity
DAPT intensification
Intensification of standard dose DAPT due to high platelet reactivity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaiser Franz Josef Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Guenter Christ
Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guenter Christ, MD
Role: PRINCIPAL_INVESTIGATOR
Kaiser Franz Josef Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Franz Josef Hospital
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
IDEAL-PCI Registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDEAL-PCI v.2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.